Congratulations to the CRCI2NA researchers for their article on the use of astatine-211 for radiotherapy, which has graced the cover of eBioMedicine, published by The Lancet, in July 2024.
The study focuses on the effectiveness of intratumoral radiotherapy with astatine-211. This radionuclide, when combined with a monoclonal antibody, targets syndecan-1, a surface protein and biomarker for glioblastoma. Results observed in female mice suggest that this method could be a promising avenue for glioblastoma treatment.
To read the full article: “Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice”
